ABCL
AbCellera Biologics Inc. (ABCL) ESG Analysis Analysis (2026)
Overall Score
Environmental
No material environmental controversies or disclosures were provided in the fresh data.
Capital intensity remains meaningful, with capex to revenue at 37.4% and capex to operating cash flow at 0.16x, suggesting ongoing resource use to support operations.
Social
No material social news was provided this month.
R&D intensity remains very high at 299.0% of revenue, indicating continued investment in innovation and talent.
Governance
The balance sheet remains strong, with a current ratio of 12.8x and low debt-to-equity of 0.15x, supporting financial resilience.
Governance risk is tempered by low leverage, but valuation remains stretched at 52.5x sales while profitability is still negative.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on AbCellera Biologics Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

